At Preston Wellness (serving Massachusetts & New Hampshire), we treat clinically confirmed low testosterone with a whole-person plan—labs, lifestyle, and careful monitoring. Many men ask: Is long-term TRT good or bad for my heart—and does it affect longevity?
Below is what the best current evidence shows.
Key Takeaways
- The largest cardiovascular outcomes RCT to date (TRAVERSE) found TRT was not inferior to placebo for major adverse cardiovascular events (MACE) in middle-aged/older hypogonadal men at elevated CV risk. However, atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often on TRT, so monitoring matters. New England Journal of Medicine+2PubMed+2
- A 2024 meta-analysis of 30 randomized trials in hypogonadal men found no increase in cardiovascular disease (CVD) or all-cause mortality with TRT. PubMed
- Large observational cohorts suggest that achieving/maintaining normal testosterone levels on therapy is associated with lower risks of death, heart attack, and stroke—though these studies can’t prove causality. PubMed+1
What the Best Trials Say About the Heart
TRAVERSE cardiovascular-outcomes trial (NEJM 2023)
In 5,246 men (45–80) with symptomatic hypogonadism and high CV risk, daily testosterone gel vs placebo for ~2 years showed no excess in the composite of CV death, MI, or stroke (met non-inferiority). Secondary safety signals included more atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group—underscoring the need for screening and follow-up. New England Journal of Medicine+1
Meta-analyses pooling RCTs
A 2024 meta-analysis (30 RCTs) concluded TRT did not increase CVD events or all-cause mortality in men with hypogonadism. This aligns with the neutral primary outcome in TRAVERSE and supports CV safety when therapy is appropriately indicated and monitored. PubMed
Regulatory context: Following these data, the FDA updated testosterone product labeling to reflect no increased risk of adverse CV outcomes for men treated for bona fide hypogonadism, while adding a blood-pressure warning for certain formulations. Reuters
Potential Cardiovascular & Longevity Advantages
While RCTs are designed for safety, several large observational cohorts show that men whose testosterone levels normalize on TRT experience lower risks of all-cause mortality, MI, and stroke compared with untreated men or men whose levels remain low. Association ≠ causation, but the signal is consistent in VA populations and others. PubMed+1
How might TRT help the heart, indirectly?
- Improved body composition & insulin sensitivity → less visceral fat, better glycemic control.
- Better anemia control & functional capacity (supported by T-Trials and other work) → improved oxygen delivery and exercise tolerance.
- Modest BP and lipid effects can trend favorable with comprehensive lifestyle care. (Mechanisms and review summaries discussed in recent expert reviews.) Nya Publishing
Safety: What to Watch Long-Term
Even with reassuring CV data overall, safe TRT requires a protocol:
- Confirm true deficiency: Symptoms plus two separate morning total testosterone values (and SHBG/free T when appropriate). Avoid “age-related low T” without clear indication. AUA Journals
- Baseline CV risk review: history of ASCVD, VTE risks, BP, lipids, diabetes, sleep apnea. (AUA advises risk assessment in all TD patients.) AUA
- Monitoring cadence:
- Hematocrit (erythrocytosis risk); hold/adjust if >54%.
- PSA & prostate per age/risk, plus symptom review.
- BP & lipids, weight/waist, A1c/fasting glucose.
- Arrhythmia/VTE vigilance (given TRAVERSE signals for AF and PE). New England Journal of Medicine
- Formulation & dosing: Use lowest effective dose to keep testosterone in physiologic range; avoid peaks/troughs that may provoke BP rise or polycythemia.
Who Might Benefit Most?
Men with documented hypogonadism plus any of the following often experience the most meaningful gains:
- Low energy, reduced exercise tolerance, anemia, low libido/ED
- Unfavorable body composition/insulin resistance despite lifestyle effort
- Osteopenia/osteoporosis needing anabolic support
When combined with nutrition counseling, progressive resistance training, sleep optimization, and cardiometabolic risk control, TRT can be part of a longevity-minded plan.
Bottom Line
- For properly selected men with true hypogonadism and good follow-up, long-term TRT appears cardiovascularly safe and may be associated with lower risks of heart events and death—particularly when therapy normalizes testosterone levels. Monitoring is non-negotiable, and clinicians should watch for AF, VTE, BP elevations, and erythrocytosis. New England Journal of Medicine+2PubMed+2
Work with Preston Wellness (MA & NH)
We follow guideline-based evaluation and monitoring so you get the benefits of TRT while minimizing risks:
- Comprehensive labs & CV risk review
- Shared decision-making on formulations/dose
- Regular follow-up for hematocrit, PSA, BP, lipids, and symptoms
- Integrated nutrition, training, and sleep plan to amplify results
👉 Book a consultation to see whether TRT fits your long-term heart-health and longevity goals.
📍 Massachusetts & New Hampshire • 📞 781-605-8158 • 🌐 prestonwellness.com
Selected References
- TRAVERSE Trial: Cardiovascular safety of testosterone-replacement therapy; noninferior for MACE but higher AF/AKI/PE signals. New England Journal of Medicine+1
- Meta-analysis (2024, 30 RCTs): No increase in CVD or all-cause mortality with TRT in hypogonadal men. PubMed
- Observational VA cohorts: Normalization of T on therapy associated with lower mortality, MI, and stroke. PubMed+1
- Guidelines (AUA): Diagnose TD with symptoms + low labs; monitor CV risk and treatment safety parameters. AUA Journals+1
- FDA label updates (2025): No increased risk of adverse CV outcomes for indicated TRT; add BP warning. Reuters
This post is for education only and isn’t medical advice. Talk with your clinician about personal risks and benefits.